Clinical Scorecard: Evaluating Risk and Implementing Preventive Strategies in Cardiomyopathies

At a Glance

Key Highlights

• High-sensitivity cardiac troponins T and I correlate with modifiable cardiovascular risk factors and predict all-cause mortality and major cardiovascular events.
• Both low and high BMI are associated with adverse outcomes in non-ischemic dilated cardiomyopathy, with lower BMI linked to worse ventricular function and fibrosis.
• ECG findings such as complete right bundle branch block and pathological anterior Q waves, combined with cardiac imaging, improve arrhythmic risk stratification.

Guideline-Based Recommendations

Diagnosis

• Use high-sensitivity cardiac troponins T and I to assess cardiac damage and risk in patients with modifiable cardiovascular risk factors.
• Perform cardiac magnetic resonance imaging to evaluate myocardial fibrosis and ventricular volumes in cardiomyopathy patients.
• Conduct ECG screening in young individuals with complete right bundle branch block and further evaluate with echocardiogram if QRS ≥130 ms or other abnormalities are present.

Management

• Implement lifestyle modifications targeting overweight, physical inactivity, poor diet, and smoking to reduce cardiac risk.
• Consider sodium–glucose cotransporter-2 inhibitors in hypertrophic cardiomyopathy patients with diabetes to reduce all-cause mortality and heart failure hospitalization.
• Monitor and manage myocardial fibrosis as a predictor of life-threatening arrhythmias.

Monitoring & Follow-up

• Regularly monitor hsTnT/I levels in patients with multiple modifiable cardiovascular risk factors.
• Follow-up with cardiac imaging and ECG to assess progression of myocardial fibrosis and arrhythmic risk.
• Observe exercise intensity effects in carriers of titin variants, noting no significant association with adverse cardiac outcomes.

Risks

• Presence of ≥3 modifiable cardiovascular risk factors increases hsTnT/I and mortality risk.
• Low BMI in non-ischemic dilated cardiomyopathy is linked to higher mortality, heart transplantation, and arrhythmic events.
• Abnormal ECG findings such as pathological anterior Q waves and prolonged QRS duration increase risk of life-threatening arrhythmias.

Patient & Prescribing Data

Hypertrophic cardiomyopathy patients with diabetes

Use of sodium–glucose cotransporter-2 inhibitors is associated with significantly lower risk of all-cause death and heart failure hospitalization over median 3.1 years follow-up.

Clinical Best Practices

• Incorporate multimodal risk stratification combining biomarkers, ECG, and cardiac imaging for comprehensive assessment.
• Recommend echocardiographic evaluation in young patients with complete right bundle branch block and abnormal ECG features.
• Promote lifestyle interventions addressing modifiable cardiovascular risk factors to reduce cardiac damage and improve outcomes.
• Consider SGLT2 inhibitors as part of pharmacotherapy in diabetic hypertrophic cardiomyopathy patients.
• Recognize myocardial fibrosis as a key prognostic marker and monitor accordingly.

References

• Association of modifiable lifestyle risk factors with high-sensitivity troponin T and I concentrations and clinical outcomes
• Body mass index, regional adipose deposition, and clinical outcomes in non-ischemic dilated cardiomyopathy: a prospective cohort study
• Prevalence and clinical significance of electrocardiographic complete right bundle branch block in young individuals
• Arrhythmic risk stratification in patients with left ventricular ring-like scar
• Exercise intensity and cardiac disease development in carriers of titin variants
• Global prevalence of myocardial fibrosis among individuals with cardiometabolic conditions: a systematic review and meta-analysis
• Sodium-glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study